-
Topical treatments in lentigo maligna | ACCREDITED | 60 mins
In this recorded webinar from MIA’s Clinical Webinar series, experts present the latest evidence and clinical guidance on managing lentigo maligna with topical therapy.
Skin Cancer GP A/Prof Paul Fishburn is joined by MIA Dermatologist Prof Pascale Guitera, who explores early diagnosis of lentigo maligna, patient-centred management strategies and key findings from the RADICAL trial. Through case-based discussion, Prof Guitera also outlines the imiquimod treatment protocol and recommended follow-up approach.
The session concludes with a Q&A led by A/Prof Paul Fishburn, where audience questions are addressed.
This webinar is suitable for Skin Cancer Doctors, General GPs, Nurses, Dermatologists and other healthcare professionals.
RESOURCES
LEARNING OUTCOMES
By the end of this presentation, you will be able to:- Describe the key clinical and dermoscopic features of facial lentigo maligna to facilitate early diagnosis.
- Compare management options of surgery, radiotherapy and topical imiquimod, and describe where non-surgical treatments may be indicated.
- Describe topical imiquimod treatment protocol and appropriate dose titration.
- Identify best practices for monitoring treatment response to topical imiquimod and long term follow up for patients.
ACCREDITATION
This activity (1221714) is allocated 1 EA CPD hour in the RACGP 2023-25 CPD Program.
This activity (36626) is allocated 1 EA CPD hour in the ACRRM CPD Program.
This activity (10117) is allocated 1 EA CPD hour in the SkinPro CPD Program.
A Statement of Completion will be provided at the end of this module for your CPD records.
SPEAKER
Prof Pascale Guitera Dermatologist, Melanoma Institute Australia and Royal Prince Alfred Hospital | Professor, The University of Sydney Declaration of Interest
HOST
A/Prof Paul Fishburn Associate Professor, The University of Queensland | Skin Cancer GP, Norwest Skin Cancer Centre | Education Committee Member, Melanoma Institute Australia
Please note that this presentation was accurate at the time of recording (May 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.
MIA’s Education Program is proudly supported through unrestricted educational grants from: 
Topical treatments in lentigo maligna | ACCREDITED | 60 mins
Free
